Slide 1: Managing Director's Report 6 Months to 31 January 2018
For personal use only Managing Director’s Report 6 Months to 31 January 2018 21 March 2018
Slide 2: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to adults, infants and children. 1
Slide 3: Half Year Performance Highlights
Half Year Performance Highlights For personal use only Total half year Revenue New products released to $31.0m up 60% develop additional market segments in Omega 3 on HY17 $19.4m driven by gummies improved demand Inventory at $18.5m Net Profit $3.2m up flat to FY17 full year 209% on HY17 $1.0m.
Slide 4: Half Year 2018 Results
For personal use only Half Year 2018 Results AUD million 4D Reported 4D Reported 60% year on year revenue 31 Jan 2018 31 Jan 2017 growth Revenue $31.0 $19.44 Australia/NZ key growth EBITDA $4.7 $1.7 region NPBT $4.4 $1.4 EBITDA $4.7m (PY $1.7m) Tax ($1.2) ($0.4) Fixed costs managed $3.7m NPA
Slide 5: Balance Sheet January 2018
Balance Sheet 31 January 2018 For personal use only AUD million Reported Reported Movement Cash balance 31 Jan 2018 31 July 2017 strong $6.7m Cash $6.7 $5.9 +$0.8m Trade receivables Trade $12.6 $12.1 +$0.5m flat to FY17 close Receivables Inventories $18.5 $18.8 -$0.3m Inventory levels maintain
Slide 6: Sales by Geography & Product
For personal use only Sales by Geography & Product Sales across key regions Encapsulated Tuna oil have grown during HY18 leads sales revenue with compared to HY17 encapsulated Algal oils and Australia/NZ major growth other oils represented in region for IF for the other products Chinese market
Slide 7: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Infant Market formula Development customers Product Development 6
Slide 8: Growth Platform: Infant formula provides further growth
For personal use only Growth Platform Market Infant formula Development customer s Infant formula provides further growth Product Development Increased Chinese demand and stability of regulations has driven increased volume across key markets Key customers have achieved or are in the process of
Slide 9: Growth Platform: Products for new segments
Market Infant formula For personal use only Development customers Growth Platform Product Development Products for new segments Clover’s Hypoallergenic DHA product is now an ingredient across multiple goat IF brands A new highly concentrated DHA product which delivers 60% oil loading in a powder
Slide 10: Growth Platform: New markets development
For personal use only Growth Platform Market Development Infant formula customers New markets development Product Development Clover’s revenue growth has been enhanced by sales into the USA, Europe and Asia Australia & New Zealand have delivered significant growth as the IF market increases volu
Slide 11: 2HFY18 Outlook & Priorities
For personal use only 2HFY18 Outlook & Priorities Continued demand in the second half based on the existing activity levels and status of Chinese regulations Expansion of production base to meet growth in demand Development of new products targeting sports nutrition, children’s and seniors’ he
Slide 12: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s